A microdose of shrooms is a very small amount of dried psilocybin mushrooms, typically between 0.1 and 0.5 grams, taken not to trip but to produce subtle, “sub-perceptual” effects. That’s roughly one-tenth to one-twentieth of what someone would take for a full psychedelic experience. At this dose, you shouldn’t experience hallucinations, visual distortions, or any significant alteration to your normal state of consciousness.
How Much Is a Microdose?
The most commonly referenced range is 0.1 to 0.5 grams of dried psilocybin mushrooms (usually Psilocybe cubensis, the most widely available species). Most people who microdose start at the lower end, around 0.1 grams, and adjust upward based on how they respond. The goal is to find the highest dose that doesn’t produce noticeable psychedelic effects.
That range matters because psilocybin content varies significantly from mushroom to mushroom, even within the same batch. Two dried mushrooms of the same weight can contain meaningfully different amounts of psilocybin. People who microdose regularly often grind a batch into a fine powder and mix it thoroughly before measuring, which helps even out those natural inconsistencies. A digital scale that reads to at least 0.01 grams is essential. Eyeballing a tenth of a gram is nearly impossible, and the difference between a sub-perceptual dose and one that makes your workday very interesting can be just a fraction of a gram.
What It Feels Like
The defining feature of a microdose is that it doesn’t feel like much at all. Researchers define it not by a specific weight but by the subjective experience: a microdose is any amount where a normal state of consciousness is maintained. You shouldn’t feel “high” or impaired. People who microdose often describe subtle shifts rather than obvious effects, things like a slightly elevated mood, a mild sense of openness, or feeling a bit more present. Some report nothing noticeable on any given dose day.
If you’re seeing visual changes, feeling waves of emotion, or noticing that music sounds dramatically different, that’s crossed into macrodose territory. The line between the two is personal. Individual sensitivity to psilocybin varies widely, which is why most protocols recommend starting low and adjusting. One study noted that negative bodily sensations like mild nausea or physical discomfort were more common with active microdoses than with placebo, even when mood and cognitive effects were minimal.
How Microdosing Schedules Work
People don’t microdose every day. The two most popular protocols involve cycling doses with rest days built in.
- The Fadiman protocol: One dose day, followed by two days off, repeated for several weeks before taking a longer break. So you might dose on Monday, take Tuesday and Wednesday off, dose again Thursday, and so on. This schedule was popularized by psychologist James Fadiman and remains the most widely used.
- The Stamets protocol: Named after mycologist Paul Stamets, this approach involves dosing four days on, three days off. It often combines the psilocybin microdose with non-psychoactive mushroom supplements (like lion’s mane) and other nutrients, based on Stamets’ hypothesis that the combination supports brain health.
Both protocols include rest days to prevent tolerance buildup. Psilocybin activates serotonin receptors, and those receptors become less responsive with repeated stimulation. Without breaks, the same dose would likely stop producing any effect at all.
How Psilocybin Works in the Brain
When you eat psilocybin mushrooms, your body converts the psilocybin into psilocin, which is the compound that actually affects your brain. Psilocin binds to serotonin receptors, particularly a type called 5-HT2A. These receptors play a role in mood, perception, and cognition. At full doses, psilocin occupies up to 72% of these receptors, producing the classic psychedelic experience: visual distortions, altered sense of time, and profound shifts in perception.
The intensity of the experience tracks closely with how many of those receptors are occupied. Brain imaging research has shown that even at relatively low occupancy levels (around 43% in one subject who received a small dose), noticeable perceptual effects can occur. A true microdose presumably occupies far fewer receptors, staying below the threshold where effects become conscious. The theory behind microdosing is that this low-level receptor stimulation could still influence mood, creativity, or cognition without producing a trip. Whether that actually happens in a meaningful, consistent way is a separate question.
What the Science Actually Shows
The honest answer is that placebo-controlled research has not confirmed most of the benefits people associate with microdosing. Two double-blind trials testing psilocybin microdoses against placebo found no significant effects on attention, mood, cognitive control, or self-reported well-being. Some initial signals appeared in areas like social cognition and self-reported mental flexibility, but those results didn’t hold up under stricter statistical analysis. Multiple other placebo-controlled studies have reached similar conclusions, finding no acute changes in cognition or mood-related measures.
This doesn’t necessarily mean microdosing does nothing. It may mean the effects are too subtle for current study designs to capture, or that they’re largely driven by expectation. The placebo effect is powerful, especially for subjective experiences like mood and creativity, and people who choose to microdose typically expect it to help. One interesting finding from microdose-range studies with LSD showed that very low doses altered how people perceive time, causing them to overestimate the length of time intervals. That suggests sub-perceptual doses can influence basic cognitive processes, even if the person doesn’t consciously notice.
The gap between anecdotal reports and clinical findings remains one of the central puzzles in this area. Thousands of people report genuine improvements in their daily lives from microdosing, but controlled studies keep failing to separate those improvements from placebo responses.
Safety Risks and Who Should Avoid It
Microdosing carries a lower risk profile than full psychedelic doses, but it’s not risk-free, and certain people face serious dangers.
Psilocybin is contraindicated for anyone with a personal or family history of psychotic disorders like schizophrenia or schizoaffective disorder, or bipolar I disorder. Even small amounts can potentially trigger psychotic episodes in vulnerable individuals. People who experience psychotic symptoms alongside depression also fall into this high-risk category, as do those who have previously had adverse reactions to psychedelics such as prolonged psychosis or suicidal thoughts.
Because psilocin activates serotonin receptors, combining it with medications that also raise serotonin levels creates a risk of serotonin syndrome, a potentially life-threatening condition. SSRI antidepressants and MAO inhibitors are the most common concern. People with epilepsy, severe cardiovascular disease, uncontrolled blood pressure, a history of heart attack or stroke, or who are pregnant should also avoid psilocybin entirely. Those with significant unprocessed trauma who haven’t yet developed coping strategies face elevated psychological risk as well.
Legal Status
Psilocybin remains a Schedule I controlled substance under U.S. federal law, meaning it is illegal to possess, produce, or distribute regardless of the amount. At the state and local level, the picture is more varied. Oregon and Colorado have both decriminalized psilocybin and legalized it for supervised therapeutic use under state law. Several municipalities in California, Massachusetts, Michigan, Washington state, and Washington, D.C. have also decriminalized possession, though this generally means reduced enforcement rather than full legality. Outside these jurisdictions, possessing any amount of psilocybin mushrooms carries the same legal risk whether it’s a microdose or an ounce.